Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GCK | P35557 | 14/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.59 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905406 | 1.00 | MEN1 (0.68) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL2653179 | 1.00 | MEN1 (0.68) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL12742912 | 0.91 | MAOB (0.56) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL2655545 | 0.90 | MEN1 (0.53) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL1042436 | 0.90 | LMNA (0.54) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL13891611 | 0.90 | MEN1 (0.53) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL2662217 | 0.90 | LMNA (0.54) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL1427108 | 0.90 | LMNA (0.54) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL2666193 | 0.89 | MEN1 (0.52) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL12408447 | 0.89 | MEN1 (0.66) | MEN1KMT2AGCKRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902052-B1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2012-11-28 | — | — | EP | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | MEN1 3153/4885KMT2A 2216/4885GCK 3/4885 |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, GCKR, GALK1 | MEN1 2732/4885KMT2A 1311/4885GCK 1/4885 |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | GCK, GALK1, PDXK | MEN1 1652/4885KMT2A 1309/4885GCK 1/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | MEN1 3690/4885KMT2A 1445/4885GCK 1/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | MEN1 3412/4885KMT2A 2260/4885GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.